Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 854

The DOI matches its Crossref record; 828 of the 828 references it cites were found in a registry or an index.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Open access
Bandelow, Borwin, Zohar, Joseph, Hollander, Eric, Kasper, Siegfried, Möller, Hans-Jürgen, WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, Borwin, Zohar, Joseph, Hollander, Eric, Kasper, Siegfried, Möller, Hans-Jürgen, WFSBP TASK FORCE ON TREATMENT GUIDE·2008·The World Journal of Biological Psychiatry
DOI 10.1080/15622970802465807
Open this paper in CoChat — free account

Abstract

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15622970802465807

Cites

828 of 828 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 828 references

Research works printed but not linked: 114

  1. Altshuler LL, 2001, Postgrad Med, 1
  2. Amore M, 1999, Hum Psychopharmacol Clin Exp, 14, 435, 10.1002/(SICI)1099-1077(199908)14:6<435::AID-HUP109>3.0.CO;2-B · doi:10.1002/(sici)1099-1077(199908)14:6<435::aid-hup109>3.0.co;2-b
  3. Bakish D, 1996, Psychopharmacol Bull, 32, 135
  4. Ballenger JC, 2001, J Clin Psychiatry, 62, 53
  5. Bandelow B, 2004, Br J Psychiatry, 184, 271, 10.1192/bjp.184.3.271 · DOI
  6. Bandelow B, 2002, Eur Neuropsychopharmacol, 12, S364, 10.1016/S0924-977X(02)80585-5 · doi:10.1016/s0924-977x(02)80585-5
  7. Bradwejn J, 1993, Can J Psychiatry, 38, S109
  8. Braun P, 1990, J Clin Psychiatry, 51, 236
  9. Bystritsky A, 2008, Psychopharmacol Bull, 41, 46
  10. 10.3109/10401239909147053 · doi:10.3109/10401239909147053
  11. Chao IL, 2004, Pharmacopsychiatry, 37, 239, 10.1055/s-2004-832600 · doi:10.1055/s-2004-832600
  12. Charney DS, 1989, J Clin Psychiatry, 50, 418
  13. Charney DS, 1986, J Clin Psychiatry, 47, 580
  14. Chouinard G, 1990, Psychopharmacol Bull, 26, 279
  15. 10.3109/10401230490281609 · doi:10.3109/10401230490281609
  16. Davis LL, 2008, Psychopharmacol Bull, 41, 8
  17. DeVeaugh-Geiss J, 1989, Psychopharmacol Bull, 25, 36
  18. Dieleman GC, 2008, Tijdschr Psychiatr, 50, 43
  19. Dunner DL, 1986, J Clin Psychiatry, 47, 458
  20. Eriksson T, 2007, Int Clin Psychopharmacol, 22, 57
  21. Feighner JP, 1987, J Clin Psychiatry (Suppl), 48, 3
  22. Feighner JP, 1982, J Clin Psychiatry, 43, 103
  23. Feltner DE, 2003, J Clin Psychopharmacol, 23, 240
  24. Ferreri M, 1994, Encéphale, 20, 785
  25. 10.1037/0022-006X.65.6.1026 · DOI
  26. Fesler FA, 1991, J Clin Psychiatry, 52, 361
  27. Foa EB, 2000, J Clin Psychiatry, 61, 43
  28. Frommberger U, 2004, Fortschr Neurol Psychiatr, 72, 411, 10.1055/s-2004-818455 · doi:10.1055/s-2004-818455
  29. Gelpin E, 1996, J Clin Psychiatry, 57, 390
  30. Gruber RP, 1971, Dis Nerv Syst, 32, 180
  31. 10.3109/10401230009147096 · DOI
  32. Hoehn-Saric R, 1988, J Clin Psychiatry, 49, 293
  33. Hoffart A, 1993, J Clin Psychiatry, 54, 481
  34. 10.1037/0022-006X.72.3.393 · DOI
  35. Hofmann SG, 2008, J Clin Psychiatry, e1
  36. Husain MM, 1993, Am J Psychiatry, 150, 1899
  37. Jenike MA, 1991, J Clin Psychiatry, 52, 13
  38. Khanna S, 1988, Convuls Ther, 4, 314
  39. Klerman GL, 199, Social Morbidity Health Care Utilization J, 265, 742
  40. Kocabasoglu N, 2004, Eur Neuropsychopharmacol, 14, S304, 10.1016/S0924-977X(04)80382-1 · doi:10.1016/s0924-977x(04)80382-1
  41. Koran LM, 2007, Am J Psychiatry, 164, 5
  42. Lee C, 2002, J Clin Psychol Psychother, 58, 1071
  43. Lenox-Smith AJ, 2003, Br J Gen Pract, 53, 772
  44. Li D, 2001, J Psychiatry Neurosci, 26, 190
  45. Lidren DM, 1994, J Consult Clin Psychol, 62, 865, 10.1037/0022-006X.62.4.865 · DOI · Paper page
  46. Liebowitz MR, 1988, J Clin Psychiatry, 49, 252
  47. 10.1002/(SICI)1520-6394(1999)10:3%3C89::AID-DA1%3E3.0.CO;2-5 · doi:10.1002/(sici)1520-6394(1999)10:3<89::aid-da1>3.0.co;2-5
  48. Livingston MG, 1994, Br J Hosp Med, 51, 281
  49. Lopes AC, 2008, Biol Psychiaty, 63, 131s, 10.1016/j.biopsych.2007.11.007 · doi:10.1016/j.biopsych.2007.11.007
  50. López-Ibor JJ, 1975, Neurological treatment in psychiatry, pain and epilepsy, 151
  51. Lum M, 1990, Biol Psychiatry :A, 27, 164
  52. Maletzky B, 1994, Convuls Ther, 10, 34
  53. Marazziti D, 1999, Am J Psychiatry, 156, 1834, 10.1176/ajp.156.11.1834-a · doi:10.1176/ajp.156.11.1834-a
  54. Marmar CR, 1996, J Clin Psychiatry, 57, 66
  55. Mavissakalian M, 1983, Psychopharmacol Bull, 19, 116
  56. Mavissakalian M, 1986, J Clin Psychol, 47, 117
  57. Meibach RC, 1987, J Clin Psychiatry, 48, 355
  58. Misri S, 2000, Can Family Phys, 46, 626
  59. Mohlman J, 2003, Am J Geriatr Psychiatry, 11, 24
  60. Montoya A, 2002, Neurosurgery, 50, 1043
  61. Munjack DJ, 1989, J Clin Psychopharmacol, 9, 22
  62. Munjack DJ, 1990, J Clin Psychiatry, 51, 35
  63. Nelson J, 1999, Can Soc Clin Pharmacol, 6, 69
  64. Neylan TC, 2006, Am J Psychiatry, 163, 2186, 10.1176/ajp.2006.163.12.2186 · DOI
  65. Nicolini H, 2008, Psychol Med, 1
  66. NIMH 1976. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy E, ECDEU Assessment manual for psychopharmacology. Revised edition. Rockville, MD: NIMH. p 217–222.
  67. Noyes R, 1996, J Clin Psychiatry, 57, 349
  68. Nutt DJ, 1998, J Clin Psychiatry, 59, 4
  69. Ontiveros A, 1992, J Psychiatry Neurosci, 17, 78
  70. Pastrana Jiménez JI, 2007, Actas Esp Psiquiatr, 35, 351
  71. Pigott TA, 1992, J Clin Psychopharmacol, 12, 11
  72. Pollack MH, 2003, Psychopharmacol Bull, 37, 53
  73. Pollack MH, 1994, J Clin Psychiatry, 55, 200
  74. Pollack MH, 1996, Psychopharmacol Bull, 32, 667
  75. Pollack MH, 1997, J Clin Psychiatry, 58, 19
  76. Pols H, 1993, Acta Psychiatr Belg, 93, 169
  77. Power KG, 1990, Br J Gen Pract, 40, 289
  78. Prasko J, 2006, Neuroendocrinol Lett, 27, 473
  79. Prasko J, 2006, Neuroendocrinol Lett, 27, 327
  80. 10.1034/j.1600-0447.2001.00263.x · DOI · Paper page
  81. Ravizza L, 1996, Psychopharmacol Bull, 32, 677
  82. 10.1037/0022-006X.70.4.86 · doi:10.1037/0022-006x.70.4.86
  83. Rickels K, 1982, J Clin Psychiatry, 43, 81
  84. Riddle MA, 1996, Psychopharmacol Bull, 32, 399
  85. Rizley R, 1986, Psychopharmacol Bull, 22, 167
  86. Rothbaum B, 1997, Bull Menninger Clinic, 61, 317
  87. Rothbaum BO, 2008, J Clin Psychiatry, e1
  88. Rück C, 2006, Capsulotomy in anxiety disorders [thesis]
  89. 10.1176/appi.ajp.164.2.290 · DOI
  90. 10.1002/da.20271 · DOI
  91. Sachdev P, 1995, J Nerv Ment Dis, 183, 408, 10.1097/00005053-199506000-00010 · doi:10.1097/00005053-199506000-00010
  92. 10.1345/aph.1C040 · doi:10.1345/aph.1c040 · Paper page
  93. Saxena S, 1996, J Clin Psychiatry, 57, 303
  94. Seedat S, 2004, J Clin Psychiatry, 65, 244
  95. Shader RI, 1993, New Engl J Med, 13, 1398
  96. Sharp DM, 1997, Br J Gen Pract, 47, 150
  97. Simon NM, 2003, Psychopharmacol Bull, 37, 66
  98. Simon NM, 2008, J Clin Psychiatry, e1
  99. Stein DJ, 1999, S Afr Med J, 89, 402
  100. 10.3109/10401230600948431 · doi:10.3109/10401230600948431
  101. Stein DJ, 2007, Eur Neuropsychophar17(Suppl, 4, S509, 10.1016/S0924-977X(07)70784-8 · doi:10.1016/s0924-977x(07)70784-8
  102. Strand M, 1990, J Clin Psychiatry (Suppl), 51, 40
  103. Tesar GE, 1991, J Clin Psychiatry, 52, 69
  104. Tiffon L, 1994, J Clin Psychiatry, 55, 66
  105. Todorov C, 2000, Can J Psychiatry, 45, 257, 10.1177/070674370004500304 · doi:10.1177/070674370004500304
  106. Turner SM, 1994, J Consult Clin Psychol, 62, 350, 10.1037/0022-006X.62.2.350 · DOI · Paper page
  107. van Ameringen M, 1993, J Clin Psychiatry, 54, 27
  108. van der Kolk BA, 1994, J Clin Psychiatry, 55, 517
  109. Wetherell JL, 2003, J Consult Clin Psychol, 71, 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
  110. WHO, 1991, Clinical Descriptions and Diagnostic Guidelines
  111. Woodman CL, 1994, J Clin Psychiatry, 55, 134
  112. Worthington JJ, 1998, Psychopharmacol Bull, 34, 199
  113. Zitterl W, 1999, Wien Klin Wochenschr, 111, 439
  114. Zohar J, 2006, Obsessive-compulsive disorder and comorbidity, 79

Cited by

See all 854

Metadata

Authors
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP TASK FORCE ON TREATMENT GUIDE
Venue
The World Journal of Biological Psychiatry
Publisher
Informa UK Limited
Published
2008-01
Volume
9
Issue
4
Pages
248-312
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
DOI
10.1080/15622970802465807
OpenAlex
W1966065460
Cited by
854
References
828
FWCI
73.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. https://app.cochat.ai/papers/10.1080/15622970802465807
The paper
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., & WFSBP TASK FORCE ON TREATMENT GUIDE. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970802465807

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.